Myasthenia Gravis: UCB Presents New Data on Zilbrysq and Rystiggo

Minimal Symptom Expression with Zilbrysq and Rystiggo

According to UCB's press release, the work focuses notably on achieving minimal symptom expression (MSE) in patients with generalized myasthenia gravis (gMG) treated with Zilbrysq (zilucoplan) or Rystiggo (rozanolixizumab). These post hoc analyses are based on a 120-week analysis of the open-label extension of the phase 3 RAISE-XT study for zilucoplan, as well as the phase 3 MycarinG study and its open-label extensions for rozanolixizumab.

James F. Howard Jr., Professor of Neurology and Medicine at the University of North Carolina at Chapel Hill, noted that evaluating treatment outcomes such as MSE over time helps better understand what represents significant disease control for patients.

Impacts of Ocular Myasthenia and Early Data on Cizutamig

UCB also presents a study on the functional, emotional, and socio-economic impact of ocular myasthenia and limited access to specialized and multidisciplinary care. This mixed-methods study included an online questionnaire and a semi-structured focus group bringing together 10 expert patients from 10 countries. The company also reports work on the CORE-5 social screening tool, which could identify clinically relevant needs not captured by traditional socio-economic indicators in Black patients with gMG, based on a panel of 207 participants who completed a 70-item questionnaire.

Interim data from a phase 1b study of cizutamig, a bispecific BCMA×CD3 T-cell engager in development, will also be presented. UCB clarifies that cizutamig, acquired through the acquisition of Candid Therapeutics, has not established its safety and efficacy and is not approved by any health authority, including the U.S. FDA.